Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 37,000 shares, a decrease of 57.0% from the August 31st total of 86,000 shares. Based on an average daily volume of 176,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are short sold.
Coeptis Therapeutics Price Performance
Shares of Coeptis Therapeutics stock opened at $0.16 on Friday. The stock’s fifty day moving average is $0.21 and its 200 day moving average is $0.28. Coeptis Therapeutics has a one year low of $0.16 and a one year high of $1.38. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.55 and a current ratio of 0.55. The stock has a market cap of $6.02 million, a P/E ratio of -0.31 and a beta of -0.91.
Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) last posted its quarterly earnings data on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Sell-side analysts anticipate that Coeptis Therapeutics will post -0.26 earnings per share for the current year.
Institutional Trading of Coeptis Therapeutics
Analysts Set New Price Targets
Separately, LADENBURG THALM/SH SH downgraded shares of Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 18th.
Check Out Our Latest Stock Report on Coeptis Therapeutics
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
Further Reading
- Five stocks we like better than Coeptis Therapeutics
- What is Put Option Volume?
- REITs on the Rise After Rate Cuts: Where to Invest Now
- What is the Dow Jones Industrial Average (DJIA)?
- Is Viking Therapeutics Ready For Another Surge?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.